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Glucose is an essential energy source for all cells. Therefore, maintaining glucose levels 
within a normal range is essential for life in vertebrates. Glucose homeostasis in the 
organism is tightly regulated by insulin, a hormone that acts on the major glucose metabolic 
tissues such as muscle, liver and adipose tissue. Insulin’s main effects include promoting 
glucose uptake, glycogen synthesis in the liver and muscle, triglyceride formation to be 
stored in adipocytes, and protein synthesis. Insulin secretion is held by the pancreatic beta-
cells, and it is modulated by glucose levels. Insufficient insulin secretion and consequent 
impairment of insulin’s actions lead to Diabetes Mellitus. 
Diabetes is a group of metabolic diseases characterized by hyperglycemia, caused by a 
defect on insulin production, insulin action or both. Type 1 diabetes in particular is due to 
an autoimmune destruction of the insulin producing pancreatic beta-cell, which usually 
leads to absolute insulin deficiency (ADA 2009). This type of diabetes accounts for 5-10% of 
the total cases of diabetes worldwide, and although its onset is commonly during childhood 
and adolescence, it can occur at any age, even during late adulthood.  
As the loss of beta-cells is determinant for the development of overt type 1 diabetes, 
understanding beta-cell’s normal physiology, namely insulin secretion, and how it may be 
affected during the progression of this disease is essential. Moreover, the development of 
new therapeutic interventions for type 1 diabetes, such as islet transplantation, beta cell 
maintenance and replacement, or stem cell therapy, requires a profound knowledge of how 
the presence of different nutrients and signals may regulate insulin secretion and beta-cell 
mass.  
In this chapter we aim to review the mechanisms involved in normal beta-cell function and 
beta-cell mass regulation, and how this function may be modulated by glucose, nutrients 
and signals in the beta-cell milieu. We also review how these mechanisms may be affected 
by the onset and progression of type 1 diabetes.  
2. Normal function of the beta-cell - glucose stimulated insulin secretion 
The pancreas is an endocrine and exocrine gland. The exocrine portion corresponds to 
acinar tissue, responsible for secreting digestive enzymes into the pancreatic juice, while the 
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endocrine portion comprises the pancreatic islets, which consist of several cell types 
secreting different hormones: -cells (insulin), -cells (glucagon), -cells (somatostatin), PP-
cells (pancreatic polypeptide) and -cells (ghrelin). The endocrine pancreas represents 1% to 
5% of the total pancreatic mass (Kim, S.K. & Hebrok, M. 2001). In the islet, beta-cells (-cells) 
are approximately 70% to 80% of the total islet cells.  
Beta-cells are responsible for secreting insulin in response to rises in blood nutrient levels 
during the postprandial state. Glucose is the most important nutrient for insulin secretion. 
The process by which glucose promotes insulin secretion requires its sensing and 
metabolism by the beta-cell, a process called glucose-stimulated insulin secretion.  
2.1 Insulin is secreted in a pulsatile and biphasic fashion 
Glucose-stimulated insulin secretion is biphasic and pulsatile (Stagner, J.I. et al. 1980). The 
secretory pulses of beta-cells are associated with synchronous Ca2+ oscillations in response to 
glucose stimulus (Bergsten, P. et al. 1994), and they have been suggested to be coupled to 
glycolysis oscillations of the beta cell (Kar, S. & Shankar Ray, D. 2005). Secretory pulses are also 
regulated and synchronized within the other islet cell types. Insulin and glucagon secretion 
show asynchronous patterns (Grapengiesser, E. et al. 2006; Stagner, J.I. et al. 1980), whereas 
somatostatin pulses are synchronized with insulin secretion (Stagner, J.I. et al. 1980).  
Glucose-stimulated insulin secretion also shows a biphasic pattern. Shortly after glucose 
stimulus, a first burst of insulin secretion occurs, followed by a decrease in the rate of 
secretion. A second sustained phase of insulin secretion can be observed just after this 
decrease, which can continue for up to several hours until euglycemia is achieved (Curry, 
D.L. et al. 1968)  (Figure 1). 
Although the mechanisms involved in the first phase of insulin secretion (termed the 
triggering pathway) are well understood, mechanisms regulating the sustained second 
phase (or the amplifying pathway) are yet to be deciphered, and different players that 
account for it have been proposed (Henquin, J.C. 2009). Notably, most of them are related to 
glucose metabolism inside the beta-cell. 
2.1.1 Mechanisms involved in the first phase of insulin secretion - the triggering 
pathway 
The first phase of glucose-stimulated insulin secretion is a multistep process that requires 
transport and oxidation of glucose, electrophysiological changes and fusion of insulin-
containing secretory granules with the beta-cell plasma membrane (Figure 1).  Glucose 
enters the cell by facilitated diffusion mediated by glucose transporters (GLUT2 in rodents, 
GLUT1 in humans). Glucose is then phosphorylated to form glucose-6-phosphate by 
glucokinase.  This enzyme plays a critical role in glucose-stimulated insulin secretion and is 
considered the glucosensor of the pancreatic beta cell.  Due to its kinetic characteristics, 
glucokinase is a determining factor for glucose phosphorylation (Matschinsky, F.M. 1996) 
and hence for its metabolism through glycolysis and oxidation.   
The generation of ATP by glycolysis, the Krebs cycle and the respiratory chain leads to 
closure of the ATP-sensitive K+ channel (KATP), a hetero-octamer comprised of four subunits 
of the sulphonylurea 1 receptor (SUR1) and four subunits of the inwardly rectifying K+ 
channel Kir6.2 (Aguilar-Bryan, L. et al. 1998). The closure of KATP channels, permit the 
background sodium (Na+) entry without balance. These two events depolarize the 
membrane to a range that allows the opening of voltage-dependent T-type calcium (Ca2+) 
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and sodium (Na+) channels. Na+ and Ca2+ entry further depolarizes the membrane and L-
type and maybe other voltage-dependent calcium channels (VDCC) open. Their activation 
triggers action potentials that increase in intracellular Ca2+ ([Ca2+]i) (Hiriart, M. & Aguilar-
Bryan, L. 2008).  Together with calcium mobilized from intracellular stores, this Ca2+ 
increase leads to fusion of insulin-containing secretory granules with the plasma membrane 
and the release of insulin into the circulation (Rorsman, P. & Renstrom, E. 2003). Following 
glucose metabolism, the rate-limiting-step for the first phase lies in the rate of signal 
transduction between sensing the rise in [Ca2+]i and exocytosis of the immediately releasable 
granules (Straub, S.G. & Sharp, G.W. 2002).  
2.1.2 Mechanisms involved in the second phase insulin secretion - the amplifying 
pathway 
The existence of a second phase of insulin secretion was first reported in the 1960s. Curry et. 
al.(Curry, D.L. et al. 1968) observed that, in total pancreas perfusion with glucose, insulin 
release showed an early and rapid increase at 2 min after glucose infusion, peaking at 4 min. 
A second or “slow” phase, characterized by an increasing rate of insulin secretion was 
sustained during the whole period of glucose infusion. On the other hand, when the 
pancreas was perfused with tolbutamide, a sulfonylurea that blocks the potassium channels, 
only the first rapid release peak was observed, suggesting this biphasic insulin secretion is 
only generated in glucose-stimulated insulin secretion (Curry, D.L. et al. 1968).  It was until 
the 1990s that evidence of mechanisms for glucose-stimulated insulin secretion independent 
of ionic action (i.e. KATP potassium channel activation) was found (Aizawa, T. et al. 1998; 
Gembal, M. et al. 1992). Since then, the concept of a rapid first phase glucose-stimulated 
insulin secretion, caused by a triggering pathway (or KATP-dependent mechanism), followed 
by a sustained second phase due to an amplifying pathway (or KATP-independent 
mechanism) has developed (Aizawa, T. et al. 2002; Henquin, J.C. 2000).  
Biphasic insulin secretion has been explained by the existence of different pools of insulin-
containing granules inside the beta cell (Aizawa, T. & Komatsu, M. 2005; Straub, S.G. & 
Sharp, G.W. 2004). There is a reserve pool of granules located in the cytoplasm which 
accounts for approximately 94% of the total granules, and a releasable pool of granules 
which are docked to the plasma membrane. It has been suggested that the docked granules 
have different ability to be released and therefore constitute two subsets, the readily 
releasable pool, and the immediately releasable pool. The granules from the immediately 
releasable pool are the first to be secreted in response to intracellular Ca2+ increase during 
the triggering pathway, leading to the first phase of insulin secretion. At the lowest point of 
secretion in between the two phases, the granules from the readily releasable pool are 
converted to the immediately releasable pool, an ATP-dependent process termed “priming”. 
This priming has been suggested to be the rate-limiting step for exocytosis, and the target 
process for signals involved in the amplifying pathway that leads to the sustained second 
phase of insulin secretion (Straub, S.G. & Sharp, G.W. 2004) (Figure 1).  Given the glucose-
stimulated nature of biphasic insulin secretion and the ATP-dependence of priming, most of 
these signals are proposed to be derived from glucose metabolism. Some of these signals are 
reviewed in the next section. 
2.2 Transcription factors regulating beta cell function 
Transcription factors in the beta-cell act in a cooperative manner, forming transcriptional 
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Fig. 1. Mechanism of biphasic glucose-stimulated insulin secretion.  
Glucose enters the cell by glucose transporters (GLUT2 in rodents, GLUT1 in humans) and 
is then phosphorylated for its metabolism through glycolysis and oxidation.  The generation 
of ATP by glycolysis, the Krebs cycle and the respiratory chain closes the ATP-sensitive K+ 
channel (KATP), allowing sodium (Na+) entry without balance. These two events depolarize 
the membrane and open voltage-dependent T-type calcium (Ca2+) and sodium (Na+) 
channels. Na+ and Ca2+ entry further depolarizes the membrane and L-type and maybe 
other voltage-dependent calcium channels (VDCC) open. This activation increases 
intracellular Ca2+ ([Ca2+]i), which leads to fusion of insulin-containing secretory granules 
with the plasma membrane and the first phase insulin secretion.  A sustained second phase 
of insulin secretion is held when the granules from the readily releasable pool are converted 
to the immediately releasable pool, an ATP-dependent process termed “priming”. Most of 
the signals involved in this process also come from glucose mitochondrial metabolism, 
comprising the amplifying pathways.  
involved in insulin gene regulation and insulin secretion, thus establishing and maintaining 
beta-cell’s phenotype and function (Lazo-de-la-Vega-Monroy, M.L. & Fernandez-Mejia, C. 
2009). Some of these factors include PDX-1, HNF4ǂ, MAFA, FOXA2 and NeuroD1 (Lazo-de-
la-Vega-Monroy, M.L. & Fernandez-Mejia, C. 2009).  
PDX-1 is one of the most important transcription factors regulating the insulin gene 
transcription. This factor is determinant for pancreatic function. -cell-specific knockout 
studies show that when pdx1 is ablated, -cell function is impaired and mice present diabetic 
phenotypes (Ahlgren, U. et al. 1998). Many of the target genes for pdx1 are crucial for 
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glucose-induced insulin secretion, such as glucose transporter glut2 (Ahlgren, U. et al. 1998), 
the insulin gene (Chakrabarti, S.K. et al. 2002), and other transcription factors (Ahlgren, U. et 
al. 1998; Chakrabarti, S.K. et al. 2002; Raum, J.C. et al. 2006; Thomas, H. et al. 2001). PDX1 
plays a role in the maintenance and proliferation of beta-cells as well (Holland, A.M. et al. 
2005).  Its overexpression in diabetic mice (Irs2 knockouts) participates in beta-cell mass 
recovery and helps ameliorate glucose tolerance (Kushner, J.A. et al. 2002), whereas pdx1 
haploinsufficiency causes -cell apoptosis (Kulkarni, R.N. et al. 2004).  
PDX1 decrease has also been associated with apoptosis and reduced expression of the anti-
apoptotic genes BclXL and Bcl-2 (Johnson, J.D. et al. 2006), defects in post-translational 
processing of insulin, inhibition of GLP-1 receptor expression (Wang, H. et al. 2005), 
glucotoxicity (Olson, L.K. et al. 1993) and lipotoxicity (Gremlich, S. et al. 1997; Hagman, D.K. 
et al. 2005).  
2.3 Metabolic coupling factors and glucose-stimulated insulin secretion 
As noted earlier, an ATP/ADP ratio increase caused by glucose metabolism in the beta-cells 
is the mechanism by which the first phase of glucose-stimulated insulin secretion is 
triggered. However, glucose metabolism can also render a series of signals, or metabolic 
coupling factors, that may initiate and sustain the second phase of insulin secretion, 
presumably by favoring mobilization of the insulin granules form the reserve pool and the 
replenishment of the immediately releasable pool of insulin granules. Some of these 
metabolic coupling factors participate in mitochondrial shuttles, involving NADPH, 
pyruvate, malate, citrate, isocitrate, acyl-CoAs, and glutamate (Jitrapakdee, S. et.al. 2010). 
There are also various signaling pathways that, when activated, may contribute to 
maintaining or increasing glucose-stimulated insulin secretion, including the CaMKII 
(Calcium-Calmodulin-Dependent Protein Kinase II) , PKA (Protein Kinase A), PKC  (Protein 
Kinase C) and PKG (Protein kinase G) pathways.  Notably, most of other insulin 
secretagogues, namely nutrients, hormones and neurotransmitters, also modulate insulin 
secretion by these pathways. 
2.3.1 Mitochondrial signalling 
The role of mitochondria in the second phase of glucose-induced insulin secretion has been 
established by several studies in cell lines and humans (Jitrapakdee, S. et.al. 2010; Maechler, 
P. & Wollheim, C.B. 2001). There is even evidence of an uncommon subform of diabetes, 
mitochondrial diabetes, where mutations in mitochondrial DNA cause pancreatic beta-cell 
dysfunction (Maechler, P. & Wollheim, C.B. 2001).  
Besides rendering the initial increase of ATP/ADP ratio, mitochondrial metabolism and 
anaplerotic metabolites are also involved in sustaining second phase insulin secretion. 
Pyruvate, the end product of glycolysis, plays an important role in this process, as it 
participates in several cycles whose final products constitute amplifying signals for insulin 
secretion. Particularly, NADPH, GTP, Malonyl-CoA, long-chain acyl-CoA, and glutamate 
have been suggested to sustain insulin secretion, although the exact mechanisms by which 
they have their effects remain to be elucidated (Jitrapakdee, S. et.al. 2010). 
Once entering the mitochondria, pyruvate may be either converted to Acetyl-CoA by 
pyruvate dehydrogenase, or carboxylated to oxalacetate by pyruvate carboxylase, and 
therefore enter the Krebs cycle (Figure 2). Notably, there is a high expression of pyruvate 
carboxylase in the pancreatic islets comparable to that in gluconeogenic tissues, but islets 
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lack phosphoenolpyruvate carboxykinase (PEPCK), the first enzyme in the glyconeogenic 
pathway (MacDonald, M.J. 1995). Moreover, several studies have correlated pyruvate 
carboxylation with insulin secretion (Han, J. & Liu, Y.Q.; Hasan, N.M. et al. 2008; Lu, D. et 
al. 2002; Xu, J. et al. 2008).  
Oxalacetate from pyruvate carboxylation may be converted to malate, exit the mitochondria, 
and re-converted to pyruvate, producing NADPH (Pyruvate/malate cycle). Oxalacetate 
may also condense with acetyl-CoA to form citrate, which either continues in the TCA cycle, 
or exits the mitochondria, and converts again to oxalacetate and acetyl-CoA by the ATP-
citrate lyase (pyruvate/citrate cycle). Oxalacetate may re-enter the pyruvate/malate cycle 
which will produce NADPH, while acetyl-CoA is carboxylated by Acetyl-CoA carboxylase 
and form malonyl-CoA, the initial step of fatty acid synthesis (Jitrapakdee, S. et.al. 2010). As 
the pancreatic islet is not a lipogenic tissue, the fact that acetyl-CoA activity is high in this 
tissue may indicate that malonyl-CoA can also act as a metabolic coupling factor for insulin 
secretion (Prentki, M. et al. 1992).  
Metabolites from the Krebs cycle can also exit the mitochondria and enter other cycles. 
Isocitrate, for example, is converted to ǂ-ketoglutarate by the NADP-dependent isocitrate 
dehydrogenase, rendering NADPH. ǂ-ketoglutarate may re-enter the mitochondria to 
continue in the TCA cycle, or can be converted to glutamate by the glutamate 
dehydrogenase (GDH). Glutamate has been suggested to be another metabolic coupling 
factor for insulin secretion, possibly by entering insulin secretory granules and promoting 
exocytosis (Maechler, P. & Wollheim, C.B. 1999).   
Finally, GTP  may be produced by an isoform of the succinyl-CoA synthetase, which 
catalyzes the conversion of succinyl-CoA to succinate in the TCA cycle. It has been 
suggested that GTP participates in insulin secretion. In beta-cells, suppression of GTP 
production by this pathway reduced glucose-induced insulin secretion, independently of 
changes in NADPH or the ATP/ADP ratio (Kibbey, R.G. et al. 2007).  
2.3.2 Calcium signaling and calcium-calmodulin-dependent protein kinase II (CaMKII) 
As noted earlier, glucose-stimulated insulin secretion is a Ca2+-mediated process. The 
increase of cytosolic calcium inside the beta-cell must be sensed and transduced in order to 
exert a secretory response. One of the candidate proteins involved in this transducing 
system is CaMK II. CaMK II activation has been correlated with glucose-stimulated insulin 
secretion. Besides being localized at the insulin secretory granules, CaMKII phosphorylates 
proteins involved in the secretory machinery, including synapsin I (Matsumoto, K. et al. 
1995), MAP-2 (microtubule-associated protein 2) (Krueger, K.A. et al. 1997), 
VAMP/synaptobrevin (Nielander, H.B. et al. 1995) and others. Insulin release is then 
suggested to be modulated by CaMK II by mobilizing the secretory granules toward the cell 
membrane by MAP-2 phosphorylation and by potentially regulating the docking or priming 
mechanisms via VAMP and synapsin I protein phosphorylation. Since CaM kinase II 
remains active after glucose stimulation, it is suggested as a mechanism of readily releasable 
pool replenishment. (Easom, R.A. 1999).  
2.3.3 The G-protein coupled signaling pathways: PKA and PKC 
The guanyl-nucleotide-binding (GTP) protein system or G-protein coupled system plays an 
important role on insulin secretion. In the beta-cells, two G-protein regulated pathways, the 
Adenylate cyclase (AC)/PKA, and the phospholipase C (PLC)/PKC pathways, modulate 
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Fig. 2. Regulation of glucose-stimulated insulin secretion by nutrients, hormones and 
neurotransmitters.  
Glucose-stimulated insulin secretion may be modulated by several mechanisms. Glucose 
metabolism increase ATP/ADP ratio and closes ATP-sensitive pottasium channels (KATP), 
depolarizing the membrane, opening voltage-dependent calcium channels (VDCC), and 
thus increasing intracellular calcium ([Ca2+]i). Glucose metabolism by the Krebs Cycle also 
renders a series of metabolic coupling factors that may initiate and sustain insulin secretion. 
These metabolic coupling factors participate in mitochondrial shuttles, involving NADPH, 
pyruvate, malate, citrate, isocitrate, acyl-CoAs, and glutamate. Signaling pathways that 
contribute to maintaining or increasing glucose-stimulated insulin secretion include PKA 
and PKC. Glucagon, glucagon-Like peptide 1 (GLP-1), and glucose-dependent 
insulinotropic peptide (GIP) act through PKA pathway, while acetylcholine and 
cholecystokinine act through the PKC pathway.  Fatty acids may contribute to insulin 
secretion through the PKC pathway through formation of diacylglycerol (DAG) or  through 
protein acylation. Aminoacids may stimulate insulin release by increasing ATP production 
from the Krebs Cycle, by membrane depolarization, or by participating in intracellular 
calcium increase.  (ǂKG: alpha-ketoglutarate, ACC: Acetyl CoA Carboxylase, FAS: Fatty 
Acid Synthase, GDH: Glutamate Dehydrogenase, GTP-SCS: GTP-Succinyl CoA Synthetase, 
ER: endoplasmic Reticulum, ME: Malic enzyme, MDH: Malate Dehydrogenase, PC: 
Pyruvate Carboxylase, PHD: Pyruvate Dehydrogenase, PIP2: Phosphatidyl Inositol 
Biphosphante, IP3: inositol 1,4,5-trisphosphate ). 
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insulin secretion in response to nutrients and other peripheral signals (Doyle, M.E. & Egan, 
J.M. 2003). Depending on the type of Gǂ subunit present, these signals will activate or 
inhibit Adenylate Cyclase (Gǂs and Gǂi subunits respectively). Gǂq subunits are associated 
with the phosphatidyl inositol system (Gomperts, B.D. et al. 2003).  
When the Adenylate Cyclase is activated in the beta-cell, it converts ATP in cyclic AMP 
(cAMP), which in turn can activate the cAMP-dependent protein kinase (PKA) and the Rap 
guanine nucleotide exchange factor (GEF) 4 or Epac2. PKA will phosphorylate several 
proteins, including L-type voltage-dependent calcium channels and proteins from the 
exocytotic machinery, increasing sustained insulin secretion (Ammala, C. et al. 1993) . Epac2 
has been shown to favor insulin secretion by increasing the size of the reserve pool and 
facilitating the recruitment of the granules to the plasma membrane (Shibasaki, T. et al. 
2007), mediating pulsatility of insulin secretion (Idevall-Hagren, O. et al. 2010), and binding 
to the SUR1 subunit of the KATP  channels (Zhang, C.L. et al. 2009). The insulin gene itself has 
cAMP response elements in its promoter that modulate insulin transcription in response to 
this nucleotide (Melloul, D. et al. 2002). 
Therefore, ligands that increase the activity of adenylate cyclase and cAMP have a positive 
effect on insulin synthesis and secretion (Sharp, G.W. 1979), while ligands that decrease 
adenylate cyclase activity affect insulin secretion in a negative way (Jones, P.M. & Persaud, 
S.J. 1998). Hormones and neurotransmitters mostly act on insulin secretion by this pathway 
(see below). 
Phospholipase C (PLC) is the other effector protein regulated by G-protein coupled 
receptors in the beta-cell. PLC activation cleaves phosphoinositides into two second 
messengers, inositol 1,4,5-trisphosphate (IP3), involved in  Ca2+ release from the 
endoplasmic reticulum, and diacylglycerol (DAG). DAG is involved in the activation of the 
Protein kinase C (PKC). PKC phosphorylates the KATP channels and the voltage-dependent 
Ca2+ channels and mobilize the secretory vesicles (Doyle, M.E. & Egan, J.M. 2003), therefore 
promoting insulin secretion. Both nutrients and neurotransmitters may act through PKC 
activation, albeit by different mechanisms. It has been proposed that nutrients may activate 
atypical isoforms of PKC (-ζ, -Ǌ, and –μ) by a non-identified mechanism independent of 
DAG, while the typical isoforms (-ǂ, -ǃ, -ǅ, and -ϵ) of PKC (Protein Kinase C) are activated 
by DAG (Jones, P.M. & Persaud, S.J. 1998).  
2.3.4 The cGMP/PKG pathway 
The cyclic GMP (cGMP) pathway is regulated basically by two factors: calcium and protein 
kinase G (PKG). Calcium increases the activity of calcium-dependent nitric oxide synthases, 
a key step in the synthesis of cGMP by soluble guanylyl cyclase (cGC). Calcium may also 
decrease cGMP synthesis by activating a calcium-dependent phosphodiesterase (PDE1). On 
the other hand, protein kinase G (PKG), an enzyme activated by cGMP, may phoshporylate 
different targets and modulate intracellular calcium concentration, primarily closing KATP 
channels (Soria, B. et al. 2004).  
Although several studies have pointed to a role of sGC and cGMP on insulin secretion 
(Laychock, S.G. et al. 1991; Russell, M.A. & Morgan, N. 2010), a precise mechanism of action 
has not been yet elucidated for this pathway. As phosphorylation of PKG has been identified 
in rat islets (Jones, P.M. & Persaud, S.J. 1998), this is likely the enzyme mediating cGMP actions 
on insulin secretion. It has also been shown that PKG activity is necessary to increase ATP 
content in response to cGMP (Vilches-Flores, A. et al. 2009), and that glucose produces small 
increases in islet cGMP content (Laychock, S.G. et al. 1991; Schmidt, H.H. et al. 1992). 
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3. Nutrient modulation of insulin secretion 
Beta-cells may be considered fuel sensors, as they are continually monitoring and 
responding to nutrient concentration in the circulation in order to secrete insulin and 
therefore, regulate glucose homeostasis. Given that meals are composed by multiple 
nutrients, it is important to examine the interplay between glucose-sensing in the beta-cell 
and other dietary nutrients, such as amino acids, fatty acids and vitamins. Cumulatively, the 
mixed nutrient sensing generates the metabolic coupling factors working as signals for 
insulin exocytosis. 
3.1 Insulin secretion in response to fatty acids 
 While it would appear that free fatty acids do not stimulate insulin secretion in the absence 
of glucose, there is a substantial body of evidence that they are essential for glucose-
stimulated insulin secretion (Salehi, A. et al. 2005). It has been proposed that, in the presence 
of glucose, fatty acid oxidation is inhibited, due to formation of malonyl-CoA by acetyl-CoA 
carboxylase. This permits the accumulation of long-chain acyl-CoA in the cytosol that then 
stimulate insulin secretion directly or through the formation of other lipid compounds such 
as diacylglycerol and various phospholipids (Nolan, C.J. et al. 2006). The mechanisms which 
could be involved in this process are (Yaney, G.C. & Corkey, B.E. 2003): a) activation of 
protein kinase-C enzymes; b) enhanced fusion of insulin-secretory vesicles with plasma 
membrane and insulin release; c) modulation of KATP channel activity directly or via 
complex lipid formation; d) Stimulation of Ca2+-ATPases; e) Protein acylation of GTP-
binding proteins; f) Inhibition of lipase activity.  
The effects of fatty acids on glucose-stimulated insulin secretion are directly correlated with 
chain length and the degree of unsaturation, where long-chain fatty acids (such as palmitate 
or linoleate) acutely improve insulin release, however, chronic increase of long-chain fatty 
acids reduce insulin release in response to glucose stimulation (Newsholme, P. et al. 2007b). 
3.2 Insulin secretion in response to amino acids. 
In addition to fatty acid involvement in glucose-stimulated insulin secretion, amino acids 
derived from dietary proteins and those released from intestinal epithelial cells, in 
combination with glucose; stimulate insulin secretion, in vivo. Amino acids individually are 
poor insulin secretagogues and a relatively small number of amino acids promote or 
synergistically enhance glucose stimulated insulin release from pancreatic beta-cells 
(Newsholme, P. et al. 2010). Leucine, glutamine, alanine, arginine, lysine, and histidine 
induce insulin secretion. The mechanisms by which these amino acids elicit insulin release 
may vary.  
Glutamine and alanine are quantitatively the most abundant amino acids in blood and 
extracellular fluids and therefore might be the most relevant to insulin secretion 
(Newsholme, P. et al. 2010).  Alanine increase ATP production in islet beta-cells, an event 
that has potential to promote the K+ATP channel triggering pathway. Alanine is also one of 
the electrogenic amino acids, being co-transported with Na+ so that its import depolarizes 
the plasma membrane and promotes Ca2+ influx, events that trigger insulin secretion 
(McClenaghan, N.H. et al. 1998). Although glutamine is rapidly transported and 
metabolized by islets, it does not promote insulin secretion by itself or enhance glucose-
stimulated insulin secretion, but can elicit insulin release in the presence of leucine 
(Newsholme, P. et al. 2007a). It is believed that this is because leucine activates glutamic 
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dehydrogenase, which then increases the capacity of glutamine to contribute to anaplerosis 
via alpha-ketoglutarate (Newsholme, P. et al. 2007a). 
Similarly as glucose-stimulated insulin release, leucine acts by generating ATP thought its 
metabolism, thus causing closure of ATP-sensitive potassium channels, membrane 
depolarization via opening of the L-voltage-dependent calcium channels, leading to calcium 
influx and increased cytoplasmic calcium concentrations. Furthermore, leucine acutely 
stimulates insulin secretion by serving as both metabolic fuel and allosteric activator of 
glutamate dehydrogenase, resulting in conversion of glutamate to 2-ketoglutarate, a 
compound that has been proposed to be a common mediator of glucose, amino acid, and 
organic acid insulin secretion (Odegaard, M.L. et al. 2010). Additionally, transamination of 
leucine to ǂ-ketoisocaproate and entry into TCA cycle via acetyl-CoA can contribute to ATP 
generation by increasing the oxidation rate of the amino acid and thus stimulation of insulin 
secretion. 
Other amino acids also stimulate insulin secretion by elevating cytosolic calcium 
concentration, although their mechanisms are achieved independently of ATP generation. 
Positive charged amino acids such as arginine, lysine and histidine, elicit insulin secretion 
by beta-cell inward transport of positive charge, triggering depolarization of cytoplasm 
membrane, and influx of extracellular calcium (Newsholme, P. et al. 2010).  
3.3 Insulin secretion in response to vitamins 
3.3.1 Vitamin A 
Vitamin A is found in the organism either as retinol, retinal or retinoic acid forms. Retinoic 
acid is the active form, and the majority of its effects involve the activation of ligand-
dependent transcription factors from the superfamily of hormonal nuclear receptors. Two of 
these receptors are known: the retinoic acid receptors (RARs) and the rexinoid receptors 
(RXRs). These can bind as heterodimers to specific DNA sequences named Retinoic Acid 
Response Elements, (RAREs) in the promoters of their target genes, or interact with other 
receptors such as Vitamin D receptors (VDRs), thyroid hormone receptors and PPARs 
(Peroxisome Proliferation Activating Receptors).  
Retinol is essential for insulin secretion (Chertow, B.S. et al. 1987) and retinoic acid increases 
insulin secretion in cultured islets (Cabrera-Valladares, G. et al. 1999), presumably by its 
stimulatory effect on pancreatic glucokinase expression and activity (Cabrera-Valladares, G. 
et al. 1999). Retinoic acid is also capable of increasing insulin (Cabrera-Valladares, G. et al. 
1999) and GLUT2 mRNA (Blumentrath, J. et al. 2001).  
3.3.2 Vitamin D 
Vitamin D is syntethized under the skin thanks to exposure to UVB radiation. It can also be 
obtained from food in the form of ergocalcipherol (vitamin D2) or cholechalcipherol 
(vitamin D3). When UVB radiation is absorbed through the skin, 7-dehydrocholesterol 
reserves form the pre-vitamin D3, which is transformed into vitamin D3 (1,25(OH2)D3 ) in a 
further process, by the action of the 25(OH2)D3 hydroxylase (Holick, M.F. 2003). Vitamin D 
acts on Vitamin D receptors (VDRs), which are either in the nucleus or in the membrane, 
rendering two different mechanisms of action, genomic, and non-genomic (rapid response) 
(Norman, A.W. et al. 2001)  
Both VDRs (Johnson, J.A. et al. 1994) and 25(OH2)D3 hydroxylase are expressed in the 
pancreatic beta-cells (Bland, R. et al. 2004), suggesting there may be vitamin D synthesis and 
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effects in these cells. In vitro, 1,25(OH2)D induces the biosynthesis of insulin in rat beta-cells 
(Bourlon, P.M. et al. 1999). It has been suggested that increases in cytosolic Ca2+, a non-
genomic effect of vitamin D, can increase insulin secretion (Norman, A.W. 2006). This 
increase may be modulated by activation of the PKC (Billaudel, B.J. et al. 1995) and PKA 
(Bourlon, P.M. et al. 1997) signaling pathways (d'Emden, M.C. et al. 1989).   
3.3.3 Biotin 
Biotin is a water-soluble vitamin that acts as a prosthetic group of carboxylases. Unrelated to 
this classic role, pharmacological concentrations of biotin regulate gene expression at both 
the transcriptional and the translational level (Rodriguez-Melendez, R. & Zempleni, J. 2003; 
Zempleni, J. 2005), and have a wide repertoire of effects on systemic processes such as 
development (Watanabe, T. 1996), reproduction (Baez-Saldana, A. et al. 2009; Paul, P.K. & 
Duttagupta, P.N. 1976; Simmins, P.H. & Brooks, P.H. 1983), and metabolism 
(Dakshinamurti, K. 2005; Fernandez-Mejia, C. 2005). 
Biotin exerts beneficial effects on endocrine pancreas physiology. We have found that biotin 
stimulates insulin and pancreatic glucokinase expression(Romero-Navarro, G. et al. 1999), 
an enzyme that plays an important role in glucose homeostasis regulating insulin secretion 
in response to changes in blood glucose concentrations. Our group found that biotin 
concentrations of 10 to 1000 nM augmented glucokinase activity and mRNA abundance in 
cultured rat pancreatic islets (Romero-Navarro, G. et al. 1999).  A similar stimulatory effect 
on pancreatic glucokinase was observed in the insulinoma RIN 1046-38 cell line (Borboni, P. 
et al. 1996). A positive effect of biotin on insulin secretion has been reported (Romero-
Navarro, G. et al. 1999; Sone, H. et al. 2000; Sone, H. et al. 1999; Vilches-Flores, A. et al. 2009).  
Studies by our group (Romero-Navarro, G. et al. 1999; Vilches-Flores, A. et al. 2009) and 
others (Sone, H. et al. 2000; Sone, H. et al. 1999) have revealed that glucose-stimulated 
insulin secretion increases in response to acute exposure to pharmacological doses of biotin 
in either primary cultured islets (Romero-Navarro, G. et al. 1999), perifused pancreas  (Sone, 
H. et al. 1999) or perifused islets (Sone, H. et al. 2000). This effect of biotin on insulin 
secretion also appears to be dose-dependent (Sone, H. et al. 1999). In isolated pancreatic 
islets, using blockers and inhibitors of different signaling pathways, we have discovered 
that the induction of glucokinase mRNA and the increase on insulin secretion by biotin 
involves guanylate cyclase and PKG activation, which triggers ATP production (Vilches-
Flores, A. et al. 2009). The increase of ATP induces insulin secretion via ATP-sensitive 
potassium channels. Insulin, in an autocrine manner, activates PI3K/Akt signaling, which 
increases pancreatic glucokinase mRNA expression (Vilches-Flores, A. et al. 2009). 
Although the acute effect of biotin on in vitro insulin secretion has been well documented, 
further studies addressing the effect of this vitamin on in vivo models, resembling the actual 
doses and periods of treatment currently recommended for diabetes treatment, need to be 
done.  
4. Other modulatory signals of insulin secretion - hormones and 
neurotransmitters 
Insulin secretion in response to the plasmatic concentration of glucose can be increased or 
decreased by several hormones (including insulin itself) and neurotransmitters via 
activation of their membrane receptors on the beta-cells (Flat, P.R. 1996). The G protein 
receptors and adenylate cyclase pathway are responsible for mediating most of these effects. 
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The adenylate cyclase pathway may be activated by some neurotransmitters, like 
acetylcholine, and hormones like GLP-1. GLP-1 is also an important factor for insulin 
synthesis and secretion, having a trophic effect on the beta-cells as well (Baggio, L.L. & 
Drucker, D.J. 2007). Other modulating pathways are activated in the beta-cells in response to 
oxidative stress caused by high glucose levels, like the JNK pathway, which ablates insulin 
synthesis and interferes with its action (Kaneto, H. et al. 2006).  
4.1 Insulin and the beta-cell autocrine signaling  
Various studies have shown an autocrine role of insulin on beta-cell function and survival 
(Aikin, R. et al. 2006; Navarro-Tableros, V. et al. 2004; Xu, G.G. & Rothenberg, P.L. 1998). In 
this process, insulin binding to tyrosine-kinase receptors located in the beta-cell promotes 
the receptor’s autophosphorylation, catalyzing subsequent tyrosine phosphorylation of 
other proteins like IRS (IRS1 and IRS2). Once phosphorylated, these proteins interact with 
signaling molecules, which results in a phosphorylation cascade where PI3K, PDK and Akt 
are sequentially activated. Akt is a serine/threonine kinase which regulates cell survival, 
proliferation, growth and nutrient metabolism, through phosphorylation of different 
proteins like GSK3, FOXO and CREB (Song, G. et al. 2005). The activated receptor may act 
on the Ras signaling pathway, which in turn activates MAP kinases ERK1/2, in this way 
regulating growth, cellular differentiation and protein synthesis (Kahn, S.E. et al. 2006). In 
human islets, insulin has a positive effect on insulin production at the transcriptional level, 
as well as on beta-cell proliferation (Persaud, S.J. et al. 2008) .  
4.2 Insulin secretion in response to glucagon 
Glucagon is considered the contrarregulatory hormone of insulin, as its systemic actions are 
contrary to the ones exerted by insulin. Glucagon stimulates glucose production, glycogen 
degradation, and lipolysis. Paradoxically, it has been shown that glucagon stimulates 
insulin secretion both in rats (Kawai, K. et al. 1995) and humans (Ahren, B. et al. 1987). 
Glucagon induces a transient increase in plasma insulin up to 1 mg glucagon concentrations, 
and this increase is seen before glucose levels rise (Ahren, B. et al. 1987). There is evidence 
that the positive effect of glucagon on insulin secretion is mediated by activation of 
glucagon receptors in the beta-cells (Kawai, K. et al. 1995), and this activation may increase 
cAMP levels, leading to the PKA pathway.  
4.3 Effects of incretins on insulin secretion  
Incretins are hormones secreted in the postprandial state by the enteroendocrine cells in the 
gut. Their main physiological role is to modulate insulin secretion. Two incretins have been 
described GIP (glucose-dependent insulinotropic peptide) and GLP-1 (glucagon-like 
peptide-1) (Brubaker, P.L. 2010).  
GLP-1 is released rapidly into the circulation after oral nutrient ingestion, and its secretion 
occurs in a biphasic pattern starting with an early (within10–15 min) phase that is followed 
by a longer (30 –60 min) second phase (Herrmann, C. et al. 1995). Incretin-receptor 
activation leads to activation of adenylate cyclase and elevation of cAMP. Its actions include 
stimulation of glucose-dependent insulin secretion, induction of beta-cell proliferation, and 
enhanced resistance to islet cells apoptosis (Brubaker, P.L. 2010). GLP-1 stimulates insulin 
secretion via mechanisms that include the following: 1) direct inhibition of KATP channels, 
which leads to beta-cell membrane depolarization; 2) increases in intracellular calcium levels 
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resulting from GLP-1–dependent influx of extracellular calcium through voltage-dependent 
calcium, channels, activation of nonselective cation channels, and mobilization of 
intracellular calcium stores; 3) increases in mitochondrial ATP synthesis, which lead to 
further membrane depolarization; 4) closure of voltage-dependent potassium (Kv) channels 
and consequent reductions in Kv currents, thereby preventing beta-cell repolarization; and 
5) direct effects on beta-cell insulin storage granule exocytosis that occur distal to increases 
in ATP and intracellular calcium (Baggio, L.L. & Drucker, D.J. 2007).   
Both GIP and GLP-1 are cleaved and inactivated by the enzyme dipeptidyl peptidase 4 
(DPP4). The rapid degradation of GLP-1 by DPP4 has led to the development of 
degradation-resistant GLP-1–receptor agonists and dipeptidyl peptidase-4 inhibitors, in 
order to increase the incretin effects. These drugs are currently used for diabetes treatment 
(Brubaker, P.L. 2010).  
4.4 Neurotransmitters in the regulation of insulin secretion  
Besides nutrients, neurohormonal signals such as autonomic innervation can markedly 
modulate glucose-stimulated insulin secretion. Islets are thoroughly innervated by 
autonomic nerves, which contain an extensive variety of neuropeptide transmitters. 
Increased sympathetic activity affects insulin secretion in situations of stress, exercise and 
trauma. Activation of parasympathetic nerves before and during feeding by the smell, taste 
and digestive tract, along with incretin hormones derived from the gut are responsible for 
enhancing insulin response to meals. 
Parasympathetic neurotransmitters that stimulate insulin secretion include acetylcholine, 
vasoactive intestinal polypeptide and gastrin-releasing polypeptide. Sympathetic 
neurotransmitters inhibit insulin release; these include norepinephrine, galanin and 
neuropeptide Y. The enteroinsular axis, mediated by incretin hormones, explains why the 
insulin response to an ingested nutrient load is greater than when the same load is given 
parenterally. Gastrointestinal hormones such as gastric inhibitory peptide, glucagon-like 
peptide-1 (7-36) and cholecystokinin exert physiological relevant insulinotrophic effects 
(Flatt, P.R. 2003). In particular glucagon-like peptide-1 (7-36) has attracted attention by its 
potential role in the treatment of diabetes (see above).  
There are at least three potential sites were insulin can be modulated by hormones, peptides 
and neurotransmitters. Firstly, these may affect the ion channels that regulate membrane 
potential and calcium influx. Secondly, they may influence the mobilization of intracellular 
calcium stores, mainly the endoplasmic reticulum, and therefore cytosolic calcium 
concentration. Thirdly, they may modify the calcium sensibility of the contractile protein 
interactions that lead to the release of the insulin secretory granules (Flatt, P.R. 2003). The 
two better known targets of hormones, peptides and neurotransmitters within the beta-cell 
are related to adenylate cyclase and phospholipase C.  
Activation of adenylate cyclase produces cyclic adenosine monophosphate (cAMP), which 
inhibits calcium sequestration within intracellular stores. Activation of cAMP-dependent 
protein kinase (PKA) results in phosphorylation of intracellular proteins that enhance 
calcium sensitization. PKA also promotes phosphorylation of voltage-dependent calcium 
channels thereby increasing calcium influx (Flatt, P.R. 2003).  
Phospholipase C activation cleaves phosphatidylinosistol in the membrane producing 
inositol-1,4,5 triphosphate wich in turn inhibits calcium sequestration into the endoplasmic 
reticulum, while the adjacent cleavage product, diacylglycerol activates protein kinase C. 
Similarly to the effects of adenylate cyclase signaling pathway, activation of phospholipase 
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C alters insulin secretion by mechanisms related to calcium sensitivity and protein 
phosphorylation (Flatt, P.R. 2003).  
5. Beta-cell mass 
Besides a correct beta-cell function, the organism’s beta-cell mass is also important for 
maintaining adequate insulin production and secretion. Beta-cell mass is determined by cell 
number as well as cell size, and it increases progressively during fetal, neonatal and growth 
periods in the life of an organism, reaching a plateau during adulthood and decaying 
gradually with age (Ackermann, A.M. & Gannon, M. 2007).  
Diverse processes participate in increasing and maintaining the beta cell mass, such as 
neogenesis (newly forming of cells from precursors), proliferation (cell replication), beta-cell 
size increase (hypertrophy), and apoptosis (cell death) (Ackermann, A.M. & Gannon, M. 
2007). Although beta-cell progenitors have been identified in the pancreas (Bonner-Weir, S. 
et al. 2008; Xu, X. et al. 2008), the participation of neogenesis during post-natal and adult 
beta cell mass is limited (Dor, Y. et al. 2004), being proliferation (Meier, J.J. et al. 2008) and 
hypertrophy (Montanya, E. et al. 2000) the mainly responsible mechanisms for post-natal 
beta cell expansion (Ackermann, A.M. & Gannon, M. 2007).  The organism is also capable of 
modifying beta-cell mass depending on its insulin requirements. In insulin resistance states, 
such as pregnancy and obesity, beta-cell mass is increased (Rhodes, C.J. 2005) a process 
driven by proliferation (Ackermann, A.M. & Gannon, M. 2007). 
The mechanisms by which adult beta-cell proliferation is driven remain unknown. 
Nevertheless, some of the factors regulating this process have been identified, such as 
growth factors (growth hormone, lactogens, insulin, insulin-like growth factors), incretins, 
cell cycle proteins, and transcription factors (PDX-1) (Ackermann, A.M. & Gannon, M. 2007).  
Although many of the molecular regulators of postnatal beta-cell mass and beta-cell 
turnover have been identified in rodent models, it has been observed that human beta-cells’ 
ability to proliferate under the same signals is very restricted compared to rodent ones 
(Parnaud, G. et al. 2008). Moreover, in humans, beta-cell proliferation has suggested to occur 
only until early adulthood, as proliferation studies in humans have shown that there is no 
beta-cell replication after the first 30 years of life (Perl, S. et al. 2010).  
6. Beta-cell failure and death in type 1 DM 
Overt hyperglycemia and therefore, the onset of type 1 diabetes occurs when 70-80% of the 
beta-cell mass is gone. But the progressive loss of beta-cells is suggested to occur slowly 
over several years (Cnop, M. et al. 2005). This progressive damage may also account for a 
reduction of the first-phase insulin secretion seen in patients positive to islet cell antibodies 
but who had not developed hyperglycemia yet (Srikanta, S. et al. 1983).  Nevertheless, the 
rate of beta-cell destruction in type 1 diabetes patients is variable and so can be the first 
manifestations of the disease. While some patients, mainly children and teenagers, may 
present ketoacidosis as first sign of diabetes, others (usually adults) could show modest 
fasting hyperglycemia, which may not evolve to severe hyperglycemia nor ketoacidosis for 
several years due to remaining function of the beta-cell (ADA 2009).   
Regardless this variable nature, type 1 diabetes progression after the initiation of the 
autoimmune response may be divided in two different phases: insulitis and overt diabetes 
(Mathis, D. et al. 2001) (Figure 3).  Apoptosis of the beta-cell is present even in the initiation 
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and, evidently, both in insulitis and diabetes. These observations suggest that the beta-cell 
has a more important role in the pathophysiology of the disease than previously thought 
(Eizirik, D.L. et al. 2009; Mathis, D. et al. 2001).  
It has been proposed that beta-cell death possibly participates in the initiation of the 
autoimmune response, particularly in autoantigen presentation (Filippi, C.M. & von Herrath, 
M.G. 2007; Kaminitz, A. et al. 2007; Mathis, D. et al. 2001). It is known that beta-cells, both in 
rodents (Finegood, D.T. et al. 1995) and humans (Kassem, S.A. et al. 2000), may undergo 
physiological periods of apoptosis, particularly during the perinatal period. Moreover, viral 
infections or inflammatory cytokines may induce accumulation of misfolded proteins, causing 
ER stress, which can also lead to beta-cell apoptosis (Eizirik, D.L. et al. 2009). Immunological  
 
 
Fig. 3. Induction and progression of insulitis.  
Viral infections or inflammatory processes may lead to beta-cell apoptosis. Apoptotic beta-
cells undergoing secondary necrosis may release beta-cell antigens, which would activate 
the antigen presenting cells. These cells could activate naive T cells in the pancreatic lymph 
nodes. When T cells reencounter the islet-antigens, they are retained in the islet, releasing 
inflammatory factors and inducing insulitis. Inflammatory cytokines activate transcription 
factors NFǋǃ and STAT-1, which decrease PDX1 and GLUT1 expression, leading to 
insufficient insulin production and secretion. Activation of NFǋǃ and STAT-1 also trigger 
ER stress, apoptotic processes and beta-cell release of citokines, leading to a vicious cycle of 
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recognition of antigens released by apoptotic beta-cells undergoing secondary necrosis, 
particularly in the presence of inflammatory factors such as TNF or interferons, could be an 
important signal to activate antigen presenting cells, which may then reach the pancreatic 
lymph nodes and be recognized by T cells (Filippi, C.M. & von Herrath, M.G. 2007). When 
these T cells reencounter the islet-antigens, they are retained in the islet, triggering the 
inflammatory process or insulitis (Mathis, D. et al. 2001). 
Beta-cells also participate in the progression of insulitis (Eizirik, D.L. et al. 2009; Kaminitz, 
A. et al. 2007). Beta-cells themselves are capable of producing chemokines and cytokines in 
response to inflammatory factors such as IL-1ǃ and IFNǄ (Cardozo, A.K. et al. 2003), a 
process mediated by activation of the transcription factors NFǋǃ and STAT-1 (Cardozo, A.K. 
et al. 2001; Cnop, M. et al. 2005). This cytokines, besides promoting beta-cell death, can 
contribute to the recruitment and activation immune cells (Eizirik, D.L. et al. 2009). A 
localized inflammatory process starts within the islet beta-cell milieu, in which immune cells 
produce more inflammatory cytokines (IL-1ǃ, TNF and interferons) that would activate 
NFǋǃ and STAT-1, leading to a vicious cycle of inflammation/beta-cell destruction that 
maintains and eventually amplifies the autoimmune attack (Eizirik, D.L. et al. 2009; 
Kaminitz, A. et al. 2007).  
Once insulitis is established, selective destruction of the beta-cells occur mainly by two 
proposed mechanisms: a recognition-linked mechanism and activation-linked mechanism. 
The former involves direct recognition of the beta-cell antigens by cytotoxic T-cells, while 
the latter is caused by exposure of soluble mediators secreted by T-cells that induce beta-cell 
death (Cnop, M. et al. 2005; Mathis, D. et al. 2001) such as cytokines, perforin or Fas/Fas 
ligand interactions, nitric oxide and reactive oxygen species (Cnop, M. et al. 2005; Mathis, D. 
et al. 2001).  
Insulitis can be maintained in certain patients without evolving to overt diabetes. Studies in 
NOD mice have suggested that before the appearance of hyperglycemia, and after insulitis 
has been triggered, beta-cell function impairment precedes beta-cell apoptosis in response to 
the autoimmune attack (Strandell, E. et al. 1990). Surprisingly, beta-cell function may be 
recovered if the islets of these animals are either removed from their inflammatory milieu 
and cultured in vitro or if the inflammation is stopped with antibodies against the effector T 
cells (Strandell, E. et al. 1990), suggesting beta-cell damage in this stage is reversible. In 
addition, there is evidence that NFǋǃ activation in response to inflammatory factors  also 
reduces PDX1 and GLUT2 expression (Cardozo, A.K. et al. 2003), two proteins which are 
crucial for insulin production and secretion.  
Together with an initial loss of beta-cell function, the inflammatory process found in type 1 
diabetes appears to stimulate beta-cell proliferation during the first stage of the disease. An 
increase in beta-cell mass may maintain metabolic demands for the period before the 
development of hyperglycemia, but it may also expose more and new epitopes, favoring 
and increasing the autoimmune destruction (Akirav, E. et al. 2008).  
Given the important role of the beta-cell during the initiating and progression stages of 
insulitis that may lead to type 1 diabetes, current research is being directed toward 
maintenance and improvement of beta-cell function and mass before and during the 
inflammatory process, establishing important therapeutic targets. New therapeutic 
approaches suggest that using combinatory treatments comprising a first immune 
intervention, followed by stimulation of beta-cell proliferation and function (perhaps with 
GLP-1-receptor agonists), and maintenance of normal glucose levels, together with the 
already used immunomodulatory therapy, may help not only to stop the progression of the 
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disease, but even to recover the remaining beta-cell mass and function (Akirav, E. et al. 2008; 
Weir, G.C. & Bonner-Weir, S. 2010).   
7. Conclusions 
Type 1 diabetes is one of the most serious chronic diseases of childhood.  In spite of all the 
efforts in finding efficient therapeutic approaches for this disease, insulin keeps being the 
only effective treatment, as islet transplantation and beta-cell generation from stem cells 
have shown difficulties in getting donors or generating effective glucose-coupled insulin 
secreting cells.  
As the loss of beta-cells is determinant for the development of overt type 1 diabetes, 
understanding beta-cell normal physiology, namely insulin secretion, and how it may be 
affected during the progression of this disease is essential. Moreover, the development of 
new therapeutic interventions for type 1 diabetes, such as islet transplantation, beta cell 
maintenance and replacement, or stem cell therapy, require a profound knowledge of how 
the presence of different nutrients and signals may regulate insulin secretion and beta-cell 
mass.  
Recent studies on the different stages of type 1 diabetes have shed light on an important role 
of beta-cell in the progression of the inflammatory process, and even evidence of reversal of 
the beta-cell damage present in the disease. These findings may provide tools to propose 
new integral and combinatorial therapeutic interventions that may aid in fighting this 
disease.  
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